The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals.
Вакцина также по-прежнему доступна в рамках разрешения на использование в экстренных случаях (EUA), в том числе для лиц в возрасте от 12 до 15 лет, а также для введения третьей дозы некоторым лицам с ослабленным иммунитетом.
Что ***ть непонятно, Иоахим?????, пойди получи 30 баксов у Файзера.
И это ....
Ongoing Safety Monitoring
The FDA and Centers for Disease Control and Prevention have monitoring systems in place to ensure that any safety concerns continue to be identified and evaluated in a timely manner. In addition, the FDA is requiring the company to conduct postmarketing studies to further assess the risks of myocarditis and pericarditis following vaccination with Comirnaty. These studies will include an evaluation of long-term outcomes among individuals who develop myocarditis following vaccination with Comirnaty. In addition, although not FDA requirements, the company has committed to additional post-marketing safety studies, including conducting a pregnancy registry study to evaluate pregnancy and infant outcomes after receipt of Comirnaty during pregnancy.
сам переведешь? постмаркетинг, млять...